See the DrugPatentWatch profile for Hadlima
Hadlima is a biosimilar to the drug Humira, which is used to treat a variety of inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1][2].
When can biosimilars like Hadlima enter the market?
The market entry for biosimilars is typically tied to patent expirations and regulatory approvals. For Humira, a key patent expired in 2016 in Europe and 2023 in the United States [3]. Biosimilar versions, like Hadlima, can only be approved and marketed after these exclusivity periods have ended or after specific patent challenges have been resolved. DrugPatentWatch.com provides detailed information on patent expirations and exclusivity periods for many drugs, including Humira [3].
How does Hadlima work?
Hadlima, like Humira, is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) [1][2]. TNF-alpha is a protein that plays a significant role in the inflammation process of autoimmune diseases. By blocking TNF-alpha, Hadlima reduces inflammation and alleviates the symptoms associated with these conditions [2].
What conditions does Hadlima treat?
Hadlima is indicated for the treatment of the same conditions that Humira is approved for. These include moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease, and ulcerative colitis [1][2].
What are the potential side effects of Hadlima?
As a biosimilar, Hadlima is expected to have a similar safety profile to Humira. Common side effects can include infections (such as upper respiratory infections, sinusitis, and flu), rash, and injection site reactions [1][2]. More serious risks can include increased risk of serious infections, allergic reactions, and a potential for developing certain cancers. Patients should discuss potential risks with their healthcare provider [2].
Who manufactures Hadlima?
Hadlima is manufactured by Samsung Bioepis [1].
How does Hadlima compare to other Humira biosimilars?
Several biosimilars to Humira are available in different markets, including adalimumab-atto (Amjevita), adalimumab-aqm (Abrilada), adalimumab-bpxx (Hyrimoz), and adalimumab-yfboy (Hadlima) [4]. These biosimilars are designed to be highly similar to Humira in terms of safety, efficacy, and quality. Differences between biosimilars and the reference product, as well as among biosimilars themselves, are generally considered minor and do not impact clinical outcomes [4].
What clinical data supports Hadlima's approval?
The approval of Hadlima was based on a comprehensive data package that included analytical studies, non-clinical studies, pharmacokinetic and pharmacodynamic studies, and clinical studies [1]. These studies demonstrated the biosimilarity of Hadlima to Humira, showing no clinically meaningful differences in terms of safety, purity, and potency [1][2].
What are the regulatory hurdles for biosimilars like Hadlima?
Biosimilars undergo a rigorous regulatory review process by agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). They must demonstrate high levels of similarity to the reference product and meet stringent quality and manufacturing standards [1][4].
What is the status of Hadlima in different countries?
Hadlima has received approval in various regions, including the United States and Europe, where it is marketed under different brand names or as adalimumab [1][4]. Its availability and market access can vary by country and by specific insurance formularies.
*
**Sources:
[1] https://www.hadlima.com/
[2] https://www.humira.com/
[3] https://drugpatentwatch.com/
[4] https://www.fda.gov/drugs/biosimilars/brands-biosimilar-and-interchangeable-biosimilar-products-references-adalimumab